HCW Biologics is trading 5.9% down at $4.37 in pre-market, giving back a portion of the gains triggered by its recent reverse stock split.
- The company recently completed a 1-for-6 reverse split effective June 30, 2026, and has experienced significant price volatility in the sessions following the adjustment.
- With no fresh company-specific news or regulatory filings released overnight, the move appears to reflect standard post-split repricing and a slightly weaker tone in the broader market.